A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 49, Issue 1, 2009, Pages 30-38

  Hamilton, J Michael ^a   Harding, Matthew W ^b   Genna, Thomas ^a   Bol, David K ^a  

^a Avalon Pharmaceuticals   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

AVN944; IMPDH inhibitor; Pharmacokinetics; Safety; Tolerability

Indexed keywords

AVN 944; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; VX 944;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; ECZEMA; EDEMA; ENZYME INHIBITION; HEADACHE; HUMAN; LIMB PAIN; MALE; PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARBAMATES; DOUBLE-BLIND METHOD; HUMANS; IMP DEHYDROGENASE; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; YOUNG ADULT;

EID: 58149188090     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008325149     Document Type: Article

References (31)

1. Zimmermann A., Gu JJ, Spychala J., Mitchell B. Inosine monophosphate dehydrogenase expression: transcription regulation of the type I and type II genes. Advan Enzyme Regul. 1996 ; 36: 75-84.
2. Liu Y., Riley LB, Bohn SA, et al. Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild-type p53 expression under normal growth conditions. J Cell Physiol. 1998 ; 177: 364-376.
3. Liu Y., Bohn SA, Sherley JL Inosine-5′-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation. Mol Biol Cell. 1998 ; 9: 15-28.
4. Huang M., Ji Y., Itahana K., Mitchell B. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res. 2008 ; 32: 131-141.
5. Olah E., Kokeny S., Papp J., et al. Modulators of cancer pathways by inhibitors of guanylate metabolism. Adv Enzyme Regul. 2006 ; 46: 176-190.
6. Chong CR, Qian DZ, Pan F., et al. Identification of type I inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem. 2006 ; 49: 2677-2680.
7. Weaver ZA, Strovel JW, Chakiath M., et al. Antiangiogenic properties of the IMPDH inhibitor AVN944 [#3983]. Proc AACR. 2007 ; 48: 942.
8. Yalowitz JA, Jayaram HN Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 2000 ; 20: 2329-2338.
9. Dayton JS, Mitchell BS Type I inosine monophosphate dehydrogenase: evidence for a single functional gene in mammalian species. Biochem Biophys Res Commun. 1993 ; 195: 897-901.
10. Floryk D., Tollaksen SL, Giometti CS, et al. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′ monophosphate dehydrogenase. Cancer Res. 2004 ; 64: 9049-9056.
11. Jackson RC, Weber G., Morris HP IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 1975 ; 256: 331-333.
12. Natsumeda Y., Ohno S., Kawasaki H., et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 ; 265: 5292-5295.
13. Nagai M., Natsumeda Y., Konno Y., et al. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 1991 ; 51: 3886-3890.
14. Jain J., Alquist SJ, Ford P., et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharm. 2004 ; 67: 767-776.
15. Zimmermann AG, Gu JJ, Laliberete J., Mitchell BS Inosine- 5′monophosphate dehydrogenase regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol. 1998 ; 61: 181-209.
16. Brouwer C., Vermunt-de Koning DGM, Trueworthy RC, et al. Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer. 2006 ; 46: 434-438.
17. Lucas DL, Webster HK, Wright DG Purine metabolism in myeloid precursor cells during maturation: studies with the HL-60 cell line. J Clin Invest. 1983 ; 72: 1889-1900.
18. Price GM, Hoffbrand AV, Taheri MR, et al. Inosine monophosphate dehydrogenase activity in acute leukaemia. Leuk Res. 1987 ; 11: 525-528.
19. Gharehbaghi K., Sreenath A., Hao Z., et al. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem Pharmacol. 1994 ; 48: 1413-1419.
20. Chen L., Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel. 2007 ; 10: 403-412.
21. Hedstrom L., Gan L. IMP dehydrogenase: structure schizophrenia and an unusual base. Curr Opin Chem Biol. 2006 ; 10: 520-525.
22. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999 ; 6: 575-597.
23. Bentley R. Mycophemolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem Rev. 2000 ; 100: 3801-3825.
24. Domhan S., Muschal S., Schwager C., et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 ; 7: 1656-1668.
25. Kiguchi K., Collart FR, Henning-Chubb C., et al. Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin. Exp Cell Res. 1990 ; 187: 47-53.
26. Malek K., Boosalis MS, Waraska K., et al. Effects of the IMPdehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia: Part I. In vivo studies. Leuk Res. 2004 ; 28: 1125-1136.
27. Huang M., Ji Y., Itahana K., et al. Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res. 2008 ; 32: 131-141.
28. Avalon Pharmaceuticals. VX-944 Investigator's Brochure. Gaithersburg, MD: Avalon Pharmaceuticals ; 2003.
29. Avalon Pharmaceuticals. Study Report VS02-944-01. Gaithersburg, MD: Avalon Pharmaceuticals ; 2004.
30. Tsuge K., Kataoka M., Seto Y. Cyanide and thiocyanate levels in blood and saliva of healthy adult volunteers. J Health Sci. 2000 ; 46: 343-350.
31. Tinker JH, Michenfelder JD Sodium nitroprusside: pharmacology, toxicology and therapeutics. Anesthesiology. 1976 ; 45: 340-354.